We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Immunotherapy in Merkel cell carcinoma: role of Avelumab.
- Authors
Palla, Amruth R; Doll, Donald
- Abstract
Merkel cell carcinoma (MCC), a rare skin cancer, is associated with high mortality, especially in a metastatic setting. Though conventional chemotherapy with platinum and etoposide has had high response rates, many of the patients have had early relapse without any effective therapy thereafter. Recently, immune check point inhibitors have shown very good durable responses, leading to the approval of a programmed death-ligand 1 inhibitor Avelumab for these patients. We briefly review the epidemiology and immune basis of the pathogenesis of MCC, which therefore explains the excellent response to check point inhibitors, and throw light on future directions of immunotherapy for this cancer.
- Subjects
MERKEL cell carcinoma; CANCER immunotherapy; CANCER-related mortality; CANCER chemotherapy; ETOPOSIDE; THERAPEUTICS
- Publication
ImmunoTargets & Therapy, 2018, Vol 7, p15
- ISSN
2253-1556
- Publication type
Article
- DOI
10.2147/ITT.S135639